Priorities for developing respiratory syncytial virus (RSV) vaccines in different target populations
Respiratory syncytial virus (RSV) is a major cause of severe respiratory tract infection worldwide. but tThere is a monoclonal antibody, palivizumab, which can be used for prophylaxis, butis no licensed vaccine or clinically effective antiviral therapy. The development of an effective vaccine has be...
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Journal article |
| 言語: | English |
| 出版事項: |
American Association for the Advancement of Science
2020
|